Since ~ 15% of NSCLC patients treated with the KRASG12C inhibitor sotorasib develop resistance by enhancing EGFR signalling [79] and with clinical benefit already seen in KRASG12C CRCs [73], these findings suggest that B7-H4 could be a promising ICM target for KRASG12C inhibitor-resistant NSCLC and CRC, or in combination with KRASG12C inhibitor, anti-EGFR therapy and PD-L1 ICB. This evidence concerns the gene EGFR and non-small cell lung carcinoma.